360 related articles for article (PubMed ID: 24285312)
61. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
62. P-Glycoprotein (ABCB1) Inhibits the Influx and Increases the Efflux of
Auvity S; Caillé F; Marie S; Wimberley C; Bauer M; Langer O; Buvat I; Goutal S; Tournier N
J Nucl Med; 2018 Oct; 59(10):1609-1615. PubMed ID: 29748235
[TBL] [Abstract][Full Text] [Related]
63. PET Tracers for Imaging of ABC Transporters at the Blood-Brain Barrier: Principles and Strategies.
Luurtsema G; Elsinga P; Dierckx R; Boellaard R; van Waarde A
Curr Pharm Des; 2016; 22(38):5779-5785. PubMed ID: 27568733
[TBL] [Abstract][Full Text] [Related]
64. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
65. ABC Transporters and Drug Resistance in Patients with Epilepsy.
Feldmann M; Koepp M
Curr Pharm Des; 2016; 22(38):5793-5807. PubMed ID: 27514707
[TBL] [Abstract][Full Text] [Related]
66. Effects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide.
Tournier N; Saba W; Cisternino S; Peyronneau MA; Damont A; Goutal S; Dubois A; Dollé F; Scherrmann JM; Valette H; Kuhnast B; Bottlaender M
AAPS J; 2013 Oct; 15(4):1082-90. PubMed ID: 23907487
[TBL] [Abstract][Full Text] [Related]
67. In vivo evaluation of limiting brain penetration of probes for α(2C)-adrenoceptor using small-animal positron emission tomography.
Kawamura K; Akiyama M; Yui J; Yamasaki T; Hatori A; Kumata K; Wakizaka H; Takei M; Nengaki N; Yanamoto K; Fukumura T; Zhang MR
ACS Chem Neurosci; 2010 Jul; 1(7):520-8. PubMed ID: 22778842
[TBL] [Abstract][Full Text] [Related]
68. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
Xiao G; Black C; Hetu G; Sands E; Wang J; Caputo R; Rohde E; Gan LS
Drug Metab Dispos; 2012 Apr; 40(4):779-87. PubMed ID: 22266779
[TBL] [Abstract][Full Text] [Related]
69. Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation.
Roberts LM; Black DS; Raman C; Woodford K; Zhou M; Haggerty JE; Yan AT; Cwirla SE; Grindstaff KK
Neuroscience; 2008 Aug; 155(2):423-38. PubMed ID: 18619525
[TBL] [Abstract][Full Text] [Related]
70. Expression of ATP-binding cassette transporters at the inner blood-retinal barrier in a neonatal mouse model of oxygen-induced retinopathy.
Tagami M; Kusuhara S; Honda S; Tsukahara Y; Negi A
Brain Res; 2009 Aug; 1283():186-93. PubMed ID: 19505448
[TBL] [Abstract][Full Text] [Related]
71. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
72. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y
Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806
[TBL] [Abstract][Full Text] [Related]
73. [¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats.
Hosten B; Boisgard R; Jacob A; Goutal S; Saubaméa B; Dollé F; Scherrmann JM; Cisternino S; Tournier N
Eur J Pharm Sci; 2013 Nov; 50(3-4):520-5. PubMed ID: 23981334
[TBL] [Abstract][Full Text] [Related]
74. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
75. P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats.
Reichel V; Burghard S; John I; Huber O
Brain Res; 2011 Jan; 1370():238-45. PubMed ID: 21075088
[TBL] [Abstract][Full Text] [Related]
76. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier.
Choo EF; Kurnik D; Muszkat M; Ohkubo T; Shay SD; Higginbotham JN; Glaeser H; Kim RB; Wood AJ; Wilkinson GR
J Pharmacol Exp Ther; 2006 Jun; 317(3):1012-8. PubMed ID: 16537797
[TBL] [Abstract][Full Text] [Related]
77. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
Pharm Res; 2007 Sep; 24(9):1720-8. PubMed ID: 17380257
[TBL] [Abstract][Full Text] [Related]
78. Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis.
Kooij G; Mizee MR; van Horssen J; Reijerkerk A; Witte ME; Drexhage JA; van der Pol SM; van Het Hof B; Scheffer G; Scheper R; Dijkstra CD; van der Valk P; de Vries HE
Brain; 2011 Feb; 134(Pt 2):555-70. PubMed ID: 21183485
[TBL] [Abstract][Full Text] [Related]
79. Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier.
Chapy H; Saubaméa B; Tournier N; Bourasset F; Behar-Cohen F; Declèves X; Scherrmann JM; Cisternino S
Br J Pharmacol; 2016 Feb; 173(3):497-510. PubMed ID: 26507673
[TBL] [Abstract][Full Text] [Related]
80. Pharmacokinetic Modeling of (
García-Varela L; García DV; Kakiuchi T; Ohba H; Nishiyama S; Tago T; Elsinga PH; Tsukada H; Colabufo NA; Dierckx RAJO; van Waarde A; Toyohara J; Boellaard R; Luurtsema G
Mol Pharm; 2021 Jan; 18(1):416-428. PubMed ID: 33315404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
